[go: up one dir, main page]

CA3042945A1 - Compositions et methodes de traitement du cancer - Google Patents

Compositions et methodes de traitement du cancer Download PDF

Info

Publication number
CA3042945A1
CA3042945A1 CA3042945A CA3042945A CA3042945A1 CA 3042945 A1 CA3042945 A1 CA 3042945A1 CA 3042945 A CA3042945 A CA 3042945A CA 3042945 A CA3042945 A CA 3042945A CA 3042945 A1 CA3042945 A1 CA 3042945A1
Authority
CA
Canada
Prior art keywords
cells
cell
tumor
patient
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3042945A
Other languages
English (en)
Inventor
David Avigan
Jacalyn ROSENBLATT
Donald Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Beth Israel Deaconess Medical Center Inc
Original Assignee
Dana Farber Cancer Institute Inc
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Beth Israel Deaconess Medical Center Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3042945A1 publication Critical patent/CA3042945A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des méthodes de traitement du cancer, la composition comprenant : a. une population de cellules comprenant une fusion de cellules dendritiques/cellules tumorales ou une fusion de cellules dendritiques/vésicules extracellulaires; et b. un inhibiteur d'Indoléamine-2,3-dioxygénase (IDO) et/ou un agent d'hypométhylation (HMA).
CA3042945A 2016-11-14 2017-11-14 Compositions et methodes de traitement du cancer Abandoned CA3042945A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662421762P 2016-11-14 2016-11-14
US62/421,762 2016-11-14
US201762515891P 2017-06-06 2017-06-06
US62/515,891 2017-06-06
PCT/US2017/061593 WO2018090028A1 (fr) 2016-11-14 2017-11-14 Compositions et méthodes de traitement du cancer

Publications (1)

Publication Number Publication Date
CA3042945A1 true CA3042945A1 (fr) 2018-05-17

Family

ID=60480467

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3042945A Abandoned CA3042945A1 (fr) 2016-11-14 2017-11-14 Compositions et methodes de traitement du cancer

Country Status (5)

Country Link
US (1) US20200000896A1 (fr)
EP (1) EP3538139A1 (fr)
AU (1) AU2017356297A1 (fr)
CA (1) CA3042945A1 (fr)
WO (1) WO2018090028A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4319800A1 (fr) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US6614237B2 (en) 2000-09-18 2003-09-02 Agilent Technologies, Inc. Multiport automatic calibration device for a multiport test system
WO2017087954A1 (fr) * 2015-11-20 2017-05-26 Dana-Farber Cancer Institute, Inc. Compositions et méthodes de traitement du cancer

Also Published As

Publication number Publication date
US20200000896A1 (en) 2020-01-02
EP3538139A1 (fr) 2019-09-18
AU2017356297A1 (en) 2019-05-23
WO2018090028A1 (fr) 2018-05-17

Similar Documents

Publication Publication Date Title
CA2704232C (fr) Stimulation de l'immunite anticancereuse a l'aide de fusions de cellules dendritiques/cellules tumorales et anti-cd3/cd28
US11026921B2 (en) Compositions and methods of treating cancer
JP2011504101A5 (fr)
AU2016243628A1 (en) Compositions and methods of treating cancer
CA3012716A1 (fr) Fusions de vesicules extracellulaires et de cellules dendritiques et leurs methodes d'utilisation
US20180078626A1 (en) Compositions and methods of treating renal cell cancer
AU2016243626A1 (en) Compositions and methods of treating multiple myeloma
CA3042945A1 (fr) Compositions et methodes de traitement du cancer
CA3042944A1 (fr) Compositions et methodes de traitement du cancer
US20190343939A1 (en) Personalized vaccines

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220517

FZDE Discontinued

Effective date: 20220517